{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-179463","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.146243+00:00","generated_at":"2026-05-17T13:54:55.317681+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CytomX reports Grade 5 adverse event in CX-2051 Phase 1 trial; FDA notified, study continues","bullets":["Single Grade 5 acute kidney injury occurred in patient with solitary kidney; event believed secondary to nausea, vomiting, diarrhea.","Safety Review Committee convened July 14, 2025, supported continued study execution and enrollment.","FDA notified on July 18, 2025; company aware on July 11, 2025.","CX-2051 dose expansions at 7.2, 8.6, and 10 mg/kg each enrolled ~20 patients as planned.","Phase 1 data update expected by Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-179463","json":"https://secwatch.observer/filing/0001193125-25-179463.json","markdown":"https://secwatch.observer/filing/0001193125-25-179463.md","text":"https://secwatch.observer/filing/0001193125-25-179463.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000119312525179463/0001193125-25-179463-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000119312525179463/d925542d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:54:55.317681+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}